{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:12:48Z","timestamp":1788966768891,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2021-46-2101"],"award-info":[{"award-number":["Z-2021-46-2101"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jad.2025.119517","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:09:16Z","timestamp":1748344156000},"page":"119517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database"],"prefix":"10.1016","volume":"388","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghe","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhe","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.119517_bb0005","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.4088\/JCP.14f09631","article-title":"The safety of duloxetine during pregnancy and lactation","volume":"75","author":"Andrade","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119517_bb0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40801-022-00334-2","article-title":"Duloxetine exposure during pregnancy and the risk of offspring being born small for gestational age or prematurely: a Nationwide Danish and Swedish safety study","volume":"10","author":"Ankarfeldt","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jad.2025.119517_bb0015","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1089\/jpm.2021.0526","article-title":"Hyponatremia with antidepressant: a rare side effect from duloxetine in a child with acute leukemia","volume":"25","author":"Baig","year":"2022","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.jad.2025.119517_bb0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2025.119517_bb0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1146\/annurev-clinpsy-050817-084746","article-title":"Treatment selection in depression","volume":"14","author":"Cohen","year":"2018","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.jad.2025.119517_bb0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.encep.2016.05.006","article-title":"Antidepressant and tolerance: determinants and management of major side effects","volume":"42","author":"David","year":"2016","journal-title":"L\u2019Encephale"},{"key":"10.1016\/j.jad.2025.119517_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1874473711666180730102343","article-title":"Drug overdose-induced coma blisters: pathophysiology and clinical and forensic diagnosis","volume":"11","author":"Dinis-Oliveira","year":"2019","journal-title":"Curr. Drug Res. Rev."},{"key":"10.1016\/j.jad.2025.119517_bb0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.jad.2025.119517_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hae.14894","article-title":"Plasma-derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency","volume":"30","author":"Escobar","year":"2024","journal-title":"Haemophilia : the official journal of the World Federation of Hemophilia"},{"key":"10.1016\/j.jad.2025.119517_bb0050","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.119517_bb0055","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1101\/lm.044115.116","article-title":"Neurobiology of fear and specific phobias","volume":"24","author":"Garcia","year":"2017","journal-title":"Learning & Memory (Cold Spring Harbor, N.Y.)"},{"key":"10.1016\/j.jad.2025.119517_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2025.119517_bb0065","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.amepre.2022.05.014","article-title":"Trends in U.S. depression prevalence from 2015 to 2020: the widening treatment gap","volume":"63","author":"Goodwin","year":"2022","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.jad.2025.119517_bb0070","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199510053331407","article-title":"Hereditary hemorrhagic telangiectasia","volume":"333","author":"Guttmacher","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.119517_bb0075","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis","volume":"11","author":"Henssler","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.119517_bb0080","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2025.119517_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/appy.12178","article-title":"Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia","volume":"8","author":"Hong","year":"2016","journal-title":"Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists"},{"key":"10.1016\/j.jad.2025.119517_bb0090","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7861\/clinmed.2023-0440","article-title":"Lymphocytic oesophagitis: diagnosis and management","volume":"23","author":"Hussein","year":"2023","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.jad.2025.119517_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamapsychiatry.2023.3525","article-title":"Evaluating the liability of antidepressants to induce mania in children and adolescents with depression","volume":"81","author":"Huybrechts","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.119517_bb0100","article-title":"Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study","volume":"368","author":"Huybrechts","year":"2020","journal-title":"Bmj"},{"key":"10.1016\/j.jad.2025.119517_bb0105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","article-title":"Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis","volume":"28","author":"Kishi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.119517_bb0110","doi-asserted-by":"crossref","DOI":"10.2196\/46538","article-title":"Challenges and implications for menopausal health and help-seeking behaviors in midlife women from the United States and China in light of the COVID-19 pandemic: web-based panel surveys","volume":"10","author":"Lau","year":"2024","journal-title":"JMIR Public Health Surveill."},{"key":"10.1016\/j.jad.2025.119517_bb0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fncir.2013.00129","article-title":"Inhibitory networks of the amygdala for emotional memory","volume":"7","author":"Lee","year":"2013","journal-title":"Frontiers in neural circuits"},{"key":"10.1016\/j.jad.2025.119517_bb0120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.psychres.2018.07.044","article-title":"Antidepressants-related cardiovascular adverse events using the adverse event reporting system","volume":"268","author":"Lee","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.119517_bb0125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40261-016-0396-9","article-title":"Vortioxetine versus duloxetine in the treatment of patients with major depressive disorder: a meta-analysis of randomized controlled trials","volume":"36","author":"Li","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jad.2025.119517_bb0130","series-title":"Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment","first-page":"5132916","volume":"2024","author":"Li","year":"2024"},{"key":"10.1016\/j.jad.2025.119517_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104527","article-title":"Gut microbiota and its metabolites in depression: from pathogenesis to treatment","volume":"90","author":"Liu","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jad.2025.119517_bb0140","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.psyneuen.2013.02.009","article-title":"NGF serum levels variations in major depressed patients receiving duloxetine","volume":"38","author":"Martino","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jad.2025.119517_bb0145","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/(SICI)1097-0223(199612)16:13<1181::AID-PD93>3.0.CO;2-N","article-title":"Haemoglobinopathies","volume":"16","author":"Old","year":"1996","journal-title":"Prenat. Diagn."},{"key":"10.1016\/j.jad.2025.119517_bb0150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.jad.2025.119517_bb0155","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.pmrj.2018.07.010","article-title":"Autonomic dysreflexia as a potential adverse effect of duloxetine and amitriptyline combination therapy: a case report","volume":"11","author":"Parke","year":"2019","journal-title":"PM R"},{"key":"10.1016\/j.jad.2025.119517_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2025.119517_bb0165","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1124\/dmd.121.000633","article-title":"Metabolism of a selective serotonin and norepinephrine reuptake inhibitor duloxetine in liver microsomes and mice","volume":"50","author":"Qin","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jad.2025.119517_bb0170","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1176\/ajp.2007.164.6.900","article-title":"Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial","volume":"164","author":"Raskin","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119517_bb0175","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.jad.2025.119517_bb0180","first-page":"65","article-title":"Duloxetine-related acute dysphoria","volume":"4","author":"Sansone","year":"2007","journal-title":"Psychiatry (Edgmont (Pa. : Township))."},{"key":"10.1016\/j.jad.2025.119517_bb0185","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12888-024-05763-7","article-title":"Suspected duloxetine-induced restless legs syndrome phenotypic variant: a case report","volume":"24","author":"Shao","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.119517_bb0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/164_2018_164","article-title":"Serotonin and norepinephrine reuptake inhibitors","volume":"250","author":"Shelton","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jad.2025.119517_bb0195","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1345\/aph.1L108","article-title":"Duloxetine-associated tachycardia","volume":"42","author":"Stevens","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jad.2025.119517_bb0200","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/1756-0500-7-574","article-title":"Phagophobia: a case report","volume":"7","author":"Suraweera","year":"2014","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.jad.2025.119517_bb0205","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.0000000000207384","article-title":"The role of hereditary hemorrhagic telangiectasia in neurologic practice","volume":"100","author":"Taylor","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.jad.2025.119517_bb0210","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.nrl.2020.05.009","article-title":"Opsoclonus-myoclonus syndrome secondary to duloxetine poisoning","volume":"36","author":"Trigo L\u00f3pez","year":"2021","journal-title":"Neurologia"},{"key":"10.1016\/j.jad.2025.119517_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577144","article-title":"Refractory epilepsy associated with anti-ribosomal P antibodies successfully treated with topiramate","volume":"340","author":"Uribe-San-Mart\u00edn","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jad.2025.119517_bb0220","series-title":"FDA's Adverse Event Reporting System (FAERS)","author":"US Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.jad.2025.119517_bb0225","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/02699052.2015.1005670","article-title":"Prevalence and predictors of affective lability after paediatric traumatic brain injury","volume":"29","author":"Vasa","year":"2015","journal-title":"Brain Inj."},{"key":"10.1016\/j.jad.2025.119517_bb0230","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology"},{"key":"10.1016\/j.jad.2025.119517_bb0235","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70176","article-title":"Reproductive toxicity induced by serotonin-norepinephrine reuptake inhibitors: a pharmacovigilance analysis from 2004 to 2023 based on the FAERS database","volume":"30","author":"Xi","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jad.2025.119517_bb0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jad.2025.119517_bb0245","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jad.2025.119517_bb0250","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jacbts.2023.07.008","article-title":"Junctional ectopic tachycardia caused by Junctophilin-2 expression silencing is selectively sensitive to ryanodine receptor blockade","volume":"8","author":"Yang","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jad.2025.119517_bb0255","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1097\/DAD.0000000000002760","article-title":"Coma blister after trazodone misuse: a case report","volume":"46","author":"Yang","year":"2024","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.jad.2025.119517_bb0260","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jad.2025.119517_bb0265","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2025.119517_bb0270","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and vincristine","volume":"23","author":"Zhong","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2025.119517_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114431","article-title":"A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder","volume":"447","author":"Zhou","year":"2023","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jad.2025.119517_bb0280","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2215-0366(20)30137-1","article-title":"Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis","volume":"7","author":"Zhou","year":"2020","journal-title":"Lancet Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725009590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725009590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:34:45Z","timestamp":1778765685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725009590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"alternative-id":["S0165032725009590"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.119517","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.119517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119517"}}